Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RLMD - US75955J4022 - Common Stock

4.08 USD
-0.15 (-3.55%)
Last: 1/6/2026, 8:00:02 PM
4.16 USD
+0.08 (+1.96%)
After Hours: 1/6/2026, 8:00:02 PM
Fundamental Rating

2

Overall RLMD gets a fundamental rating of 2 out of 10. We evaluated RLMD against 191 industry peers in the Pharmaceuticals industry. The financial health of RLMD is average, but there are quite some concerns on its profitability. RLMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RLMD has reported negative net income.
RLMD had a negative operating cash flow in the past year.
RLMD had negative earnings in each of the past 5 years.
RLMD had a negative operating cash flow in each of the past 5 years.
RLMD Yearly Net Income VS EBIT VS OCF VS FCFRLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -377.61%, RLMD is not doing good in the industry: 94.76% of the companies in the same industry are doing better.
With a Return On Equity value of -593.47%, RLMD is not doing good in the industry: 81.68% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -377.61%
ROE -593.47%
ROIC N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
RLMD Yearly ROA, ROE, ROICRLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLMD Yearly Profit, Operating, Gross MarginsRLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, RLMD has more shares outstanding
The number of shares outstanding for RLMD has been increased compared to 5 years ago.
There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLMD Yearly Shares OutstandingRLMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RLMD Yearly Total Debt VS Total AssetsRLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

RLMD has an Altman-Z score of -41.50. This is a bad value and indicates that RLMD is not financially healthy and even has some risk of bankruptcy.
RLMD's Altman-Z score of -41.50 is on the low side compared to the rest of the industry. RLMD is outperformed by 91.62% of its industry peers.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.5
ROIC/WACCN/A
WACCN/A
RLMD Yearly LT Debt VS Equity VS FCFRLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.86 indicates that RLMD has no problem at all paying its short term obligations.
RLMD's Current ratio of 2.86 is in line compared to the rest of the industry. RLMD outperforms 50.26% of its industry peers.
RLMD has a Quick Ratio of 2.86. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RLMD (2.86) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
RLMD Yearly Current Assets VS Current LiabilitesRLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

RLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.28%, which is quite impressive.
EPS 1Y (TTM)37.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RLMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.59% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.66%
EPS Next 2Y33.29%
EPS Next 3Y20.06%
EPS Next 5Y9.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLMD Yearly Revenue VS EstimatesRLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
RLMD Yearly EPS VS EstimatesRLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RLMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLMD Price Earnings VS Forward Price EarningsRLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLMD Per share dataRLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as RLMD's earnings are expected to grow with 20.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.29%
EPS Next 3Y20.06%

More info and screens

0

5. Dividend

5.1 Amount

RLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

RELMADA THERAPEUTICS INC

NASDAQ:RLMD (1/6/2026, 8:00:02 PM)

After market: 4.16 +0.08 (+1.96%)

4.08

-0.15 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners18.56%
Inst Owner Change0%
Ins Owners6.69%
Ins Owner Change38.68%
Market Cap299.19M
Revenue(TTM)N/A
Net Income(TTM)-56.17M
Analysts80
Price Target10.2 (150%)
Short Float %1.5%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-85.6%
Min EPS beat(2)-153.55%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-60.41%
Min EPS beat(4)-153.55%
Max EPS beat(4)12.98%
EPS beat(8)4
Avg EPS beat(8)-25.51%
EPS beat(12)7
Avg EPS beat(12)-14.53%
EPS beat(16)9
Avg EPS beat(16)-10.64%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)900%
PT rev (3m)900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)36.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 31.61
P/tB 31.61
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -377.61%
ROE -593.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -41.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y52.66%
EPS Next 2Y33.29%
EPS Next 3Y20.06%
EPS Next 5Y9.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.7%
EBIT Next 3YN/A
EBIT Next 5Y-5.88%
FCF growth 1Y48.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.32%
OCF growth 3YN/A
OCF growth 5YN/A

RELMADA THERAPEUTICS INC / RLMD FAQ

What is the fundamental rating for RLMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to RLMD.


What is the valuation status for RLMD stock?

ChartMill assigns a valuation rating of 1 / 10 to RELMADA THERAPEUTICS INC (RLMD). This can be considered as Overvalued.


How profitable is RELMADA THERAPEUTICS INC (RLMD) stock?

RELMADA THERAPEUTICS INC (RLMD) has a profitability rating of 0 / 10.


What is the financial health of RELMADA THERAPEUTICS INC (RLMD) stock?

The financial health rating of RELMADA THERAPEUTICS INC (RLMD) is 6 / 10.


What is the earnings growth outlook for RELMADA THERAPEUTICS INC?

The Earnings per Share (EPS) of RELMADA THERAPEUTICS INC (RLMD) is expected to grow by 52.66% in the next year.